NCT01843127View on ClinicalTrials.gov

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Ranolazine

DRUG

Placebo

DRUG

Exenatide

Trial Locations (3)

32804

Translational Research Institute-Florida Hospital, Orlando

33126

SeaView Research, Inc, Miami

91911

Profil Institute for Clinical Research, Inc., Chula Vista

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT01843127 - A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes. | Biotech Hunter | Biotech Hunter